Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2005 Jan;6(1):114-21.

TAK-375 Takeda.

Author information

1
Centre for Chronobiology, Psychiatric University Clinic, Basel, Switzerland. christian.cajochen@pukbasel.ch

Abstract

TAK-375 (Ramelteon), a melatonin ML1/MT1 receptor agonist for the potential treatment of primary insomnia, is being developed by Takeda. Takeda submitted an NDA to the FDA for TAK-375 in September 2004.

PMID:
15675611
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center